Preserved arterial vasodilatation via endothelial protease‐activated receptor‐2 in obese type 2 diabetic mice

• Published in: British journal of pharmacology 2011-09, Vol.164 (2), p.358-371
• Main Authors: Kagota, Satomi, Chia, Elizabeth, McGuire, John J
• Format: Article
• Language: English
• Subjects: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid - pharmacology; Acetylcholinesterase; Alcohol Oxidoreductases; Animals; Arteries - physiology; Biological and medical sciences; Blood Glucose; Diabetes; Diabetes Mellitus, Type 2 - metabolism; Diabetes. Impaired glucose tolerance; Dose-Response Relationship, Drug; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; endothelial dysfunction; Endothelium, Vascular - enzymology; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Gene Expression Regulation, Enzymologic; Glucose - metabolism; Glycosuria; Male; Medical sciences; Metabolic diseases; Mice; Mice, Inbred C57BL; Nitric oxide; Nitroprusside; Obesity; Oligopeptides - pharmacology; Pharmacology. Drug treatments; Phenylephrine - pharmacology; Potassium - metabolism; protease‐activated receptors; Receptor, PAR-2 - genetics; Receptor, PAR-2 - metabolism; Receptors, Leptin - genetics; Receptors, Leptin - metabolism; Research Papers; resistance arteries; RNA, Messenger; Rodents; Vasodilation - physiology
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/j.1476-5381.2011.01356.x

BACKGROUND AND PURPOSE In non‐obese diabetic animals, protease‐activated receptor‐2 (PAR2) agonists are more effective vasodilators, which is attributed to increased COX‐2 and endothelial NOS (eNOS) activities. Under conditions of diabetes and obesity, the effectiveness of PAR2 agonists is unknown. We compared the vasodilator responses of small calibre mesenteric arteries from obese diabetic B6.BKS(D)‐Leprdb/J (db/db) induced by PAR2‐activating agonists 2‐furoyl‐LIGRLO‐amide (2fly) and trypsin to those obtained in controls [C57BL/6J (C57)], and assessed the contributions of COX, NOS and calcium‐activated potassium channels (KCa) to these responses. EXPERIMENTAL APPROACH Arteries mounted in wire myographs under isometric tension conditions were contracted submaximally by U46619 then exposed to vasodilators. mRNA and protein expression of PAR2, eNOS and soluble GC (sGC) were determined by real‐time PCR and Western blots. KEY RESULTS ACh‐ and nitroprusside‐induced relaxations were attenuated in db/db compared with C57. In contrast, 2fly‐ and trypsin‐induced relaxations were largely retained in db/db. A NOS inhibitor partly inhibited ACh‐ and 2fly‐induced relaxations in C57, but not those in db/db. Inhibitors of the COX‐cAMP pathway (FR122044, SC560, NS398, SC58125, SQ22536, CAY10441) did not affect these relaxation responses in either strain. Charybdotoxin (BKCa, SK3.1 blocker), but not iberiotoxin (BKCa blocker), inhibited responses to the PAR2 agonists in db/db. In db/db protein levels of eNOS were higher, whereas those of sGC were lower than in C57. PAR2 mRNA expression in db/db was higher than in C57. CONCLUSIONS AND IMPLICATIONS PAR2‐mediated vasodilatation is protected against the negative effects of obesity and diabetes in mice. In diabetic vascular dysfunction, preserved PAR2 vasodilatation was linked to activation of SK3.1.